EUCTR2007-004645-15-DE进行中（未招募）不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Children of either sex and of any race, 3 months to <18 years of age.
- •2. Subjects must have documented or anticipated neutropenia (ANC less than or equal to 500/mm3 [0.5 x 10^9/L]) expected to last for at least 7 days and only in the following clinical situations: Acute leukemia (including new and relapse), Myelodysplasia, Severe aplastic anemia, Autologous HSCT recipients, High risk neuroblastoma, Advanced stage non-Hodgkin’s lymphoma. Recipients of allogeneic HSCT during the pre-engraftment period (neutropenia period).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects with proven IFI, as defined by the MSG/EORTC criteria prior to study entry
- •2. Subjects with Grade 3 or Grade 4 nausea and/or vomiting at Screening
- •3. Subjects who have received POS within the past 10 days prior to Screening
- •4. Subjects receiving prohibited drugs (please refer to Table 3)
- •5. Subjects whose laboratory tests are outside normal limits as follows:
- •a. AST ot ALT>5 times th eupper limit of normal (ULN)
- •b. Serum total bilirubin >2.5 x ULN
- •c. Calculated creatinine clearance <30mL/min. Creatinine clearance will be calculated using the following equation:
- •Creatinine clearance = k*height (cm)/serum creatinine (mg/dL)
- •Where k = 0.45 for a full term baby less than 1 year old; 0.55 for children up to 12 years old; 0.55 for females between the ages of 13 and 21 years; 0.7 for males between the ages of 13 and 21 years
- •6. Subjects with QTc prolongation:
- •a. Symptomatic QTc prolongation >450 msec (males) or >470 msec (females)
- •b. Any QTc prolongation of >500 msec
- •7. Subjects who are unable to receive drug internally
- •8. Female subjects who are pregnant, intend to become pregnant during the course of the study, or are breast-feeding
- •9. Subjects with a history of anaphylaxis attributed to the azole class of antifungal agents.
- •10. Subjects with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study, including receiving less than 7 days of POS.
- •11. Subjects who have already participated in this study or are participating in any Phase 1 clinical study or any study for a medication that has not yet received regulatory approval.
- •12. Subjects who are part of the study staff personnel or family members of the study staff personnel.
研究者
相似试验
已完成
不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With NeutropenialeukemiaNL-OMON39331Merck Sharp & Dohme (MSD)23
进行中（未招募）
不适用
A study to look at safety and acceptance of Posaconazole (study drug) given by mouth to children with a blood illness.Treatment and prophylaxis of invasive fungal infectionsMedDRA version: 14.1Level: LLTClassification code 10062642Term: Invasive mycosisSystem Organ Class: 100000004862EUCTR2007-004645-15-GRSchering Plough Research Institute, A Division of Schering Corporation108
进行中（未招募）
1 期
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia - NDtreatment and prophylaxis of invasive fungal infectionsoropharyngeal candidiasis (OPC) and refractory OPCMedDRA version: 9.1 Level: LLT Classification code 10050346 Term: Oropharyngeal candidiasisMedDRA version: 9.1 Level: HLGT Classification code 10017528 Term: Fungal infectious disordersEUCTR2007-004645-15-ITSchering Plough Research Institute142
进行中（未招募）
不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With NeutropeniaEUCTR2007-004645-15-NLSchering Plough Research Institute, A Division of Schering Corporation108
未知
1 期
Phase 1 Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsJPRN-jRCT2080223015Bristol-Myers Squibb K.K.18